Description
The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is issuing a Request for Applications (RFA‑AI‑28‑005) to fund the Immune Tolerance Network (ITN) under a UM1 Cooperative Agreement. The network’s mission is to develop tolerogenic therapies for immune‑mediated disorders, focusing on three clinical areas: allergic diseases/asthma, autoimmune diseases, and immune‑mediated consequences of transplantation. Funded entities will design, conduct, and share results of multi‑center clinical trials, perform integrated mechanistic studies, develop immune‑assay platforms, and manage a shared data repository. The award is a single, multi‑year cooperative agreement with an estimated total funding of $21.986 million. Only one application per institution is allowed. Key dates: Open for submissions December 29 2026; application due January 29 2027; anticipated award February 1 2028; project start February 1 2028.
• Funding mechanism: UM1 Cooperative Agreement (complex‑structure research project)
• Targeted research: clinical trials and mechanistic studies in allergy, autoimmunity, and transplantation tolerance
• Eligible applicants: broad range of U.S. public, private, nonprofit, and tribal entities (one application per institution)
• Estimated total award: ≈ $22 million (single award)
• Required deliverables: data‑management & sharing plan, annual RPPRs, final close‑out reporting
• Primary contact: NIAID scientific contact, [email protected]